Proteomics Profiling and Risk of New‐Onset Atrial Fibrillation: Framingham Heart Study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Prior studies relating proteomics markers to incident AF screened for limited numbers of proteins. Methods and Results: We performed proteomics assays among participants from the Framingham Heart Study Offspring attending their fifth examination. Plasma protein levels (n=1373) were measured by the SOMAscan proteomic profiling platform. We used robust inference for the Cox proportional hazards model to relate each protein level with incident AF. In addition, we examined the association between AF‐related genetic loci and levels of proteins associated with AF. Our study included 1885 participants (mean age 55±10 years, 54% women) who had proteomic profiles measured. A total of 349 participants developed AF during follow‐up (mean follow‐up 18.3 years). We observed that 8 proteins were significantly associated with incident AF after adjusting for age, sex, technical covariates, and correction for multiple testing ( P <0.05/1373=3.6×10 −5 ). After additional adjustments for clinical factors associated with AF, ADAMTS13 and N‐terminal pro‐B‐type natriuretic peptide remained significantly associated with the risk of incident AF (hazard ratio, 0.78; 95% CI, 0.70–0.88; and 1.44; 95% CI, 1.22–1.70, respectively; P <3.6×10 −5 for both). None of the 8 proteins were encoded by genes at AF‐related genetic loci previously identified by genome‐wide association studies. Conclusions: We identified 8 proteins associated with risk of incident AF after adjustment for age and sex; 2 proteins were associated with AF after adjustment for AF risk factors. Future studies are needed to replicate our findings, identify whether the markers are mechanistically related to AF development, and whether they are clinically useful for identification of future AF risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The natural history of congestive heart failure: the Framingham study
McKee, P. A., Castelli, W. P., McNamara, P. M., & Kannel, W. B. (1971) · New England Journal of Medicine · doi:10.1056/nejm197112232852601 · Cited by 3,448
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
Meta-analysis identifies six new susceptibility loci for atrial fibrillation
Ellinor, P. T., Lunetta, K. L., Albert, C. M., Glazer, N. L., Ritchie, M. D., Smith, A. V., Arking, D. E., Müller-Nurasyid, M., Krijthe, B. P., Lubitz, S. A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2261 · Cited by 601
Self-citationPiccini, J. P., Hammill, B. G., Sinner, M. F., Jensen, P. N., Hernandez, A. F., Heckbert, S. R., Benjamin, E. J., & Curtis, L. H. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.962688 · Cited by 565
Self-citationRutter, M. K., Parise, H., Benjamin, E. J., Levy, D., Larson, M. G., Meigs, J. B., Nesto, R. W., Wilson, P. W. F., & Vasan, R. S. (2003) · Circulation · doi:10.1161/01.cir.0000045671.62860.98 · Cited by 511
Self-citationGanz, P., Heidecker, B., Hveem, K., Jonasson, C., Kato, S., Segal, M. R., Sterling, D. G., & Williams, S. A. (2016) · JAMA · doi:10.1001/jama.2016.5951 · Cited by 364 · cited 1×
“The technology has been validated in a study of cardiovascular disease.(26,30) Samples were assayed in 2 batches (n=821 and 1092, respectively).”
MethodPatton, K. K., Ellinor, P. T., Heckbert, S. R., Christenson, R. H., DeFilippi, C., Gottdiener, J. S., & Kronmal, R. A. (2009) · Circulation · doi:10.1161/circulationaha.109.873265 · Cited by 310
Self-citationSinner, M. F., Tucker, N. R., Lunetta, K. L., Ozaki, K., Smith, J. G., Trompet, S., Bis, J. C., Lin, H., Chung, M. K., Nielsen, J. B., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.009892 · Cited by 205
Self-citationMathew, J. S., Sachs, M. C., Katz, R., Patton, K. K., Heckbert, S. R., Hoofnagle, A. N., Alonso, A., Chonchol, M., Deo, R., Ix, J. H., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005499 · Cited by 153
Filion, K. B., Agarwal, S. K., Ballantyne, C. M., Eberg, M., Hoogeveen, R. C., Huxley, R. R., Loehr, L. R., Nambi, V., Soliman, E. Z., & Alonso, A. (2015) · American Heart Journal · doi:10.1016/j.ahj.2014.10.005 · Cited by 73
Cited by
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Van Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,024
Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights
Kornej, J., Börschel, C. S., Benjamin, E. J., & Schnabel, R. B. (2020) · Circulation Research · doi:10.1161/circresaha.120.316340 · Cited by 1,516
Self-citationKatz, D. H., Robbins, J. M., Deng, S., Tahir, U. A., Bick, A. G., Pampana, A., Yu, Z., Ngo, D., Benson, M. D., Chen, Z.-Z., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm5164 · Cited by 206
Self-citationSOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH
Luo, Y., Wadhawan, S., Greenfield, A., Decato, B. E., Oseini, A. M., Collen, R., Shevell, D. E., Thompson, J., Jarai, G., Charles, E. D., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1670 · Cited by 87
“(11) SOMAscan has been used to identify diagnostic signatures of several other diseases.(12-14) In this study, the SOMAscan proteomics approach was used to identify biomarkers that distinguish fibrosis stages, particularly advanced fibrosis, in a population of patients with NASH.”
Method
Metadata
- Authors
- Ko, D., Benson, M. D., Ngo, D., Yang, Q., Larson, M. G., Wang, T. J., Trinquart, L., McManus, D. D., Lubitz, S. A., Ellinor, P. T., Vasan, R. S., Gerszten, R. E., Benjamin, E. J., & Lin, H.
- Venue
- Journal of the American Heart Association
- Published
- 2019-03-19
- Volume
- 8
- Issue
- 6
- Pages
- e010976-e010976
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2922347496
- Cited by
- 65
- References
- 10
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteomics Profiling and Risk of New‐Onset Atrial Fibrillation: Framingham Heart Study. https://app.cochat.ai/papers/10.1161/jaha.118.010976
- The paper
- Ko, D., Benson, M. D., Ngo, D., Yang, Q., Larson, M. G., Wang, T. J., Trinquart, L., McManus, D. D., Lubitz, S. A., Ellinor, P. T., Vasan, R. S., Gerszten, R. E., Benjamin, E. J., & Lin, H. (2019). Proteomics Profiling and Risk of New‐Onset Atrial Fibrillation: Framingham Heart Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.118.010976
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.